BLG



Spectral Medical Inc. completes C\$10 million Bought Deal Financing

Date : 2/18/16

Value : C\$10.6 million

On February 18, 2016, <u>Spectral Medical Inc.</u> (the Company) completed a bought deal financing by way of short form prospectus of 14,300,000 common shares of the Company at a price of C\$0.70 per common share, for gross proceeds of C\$10,010,000. The Underwriters were also granted an over-allotment option to purchase up to an additional 2,145,000 common shares. The Underwriters partially exercised the over-allotment option and purchased an additional 806,804 common shares resulting in total gross proceeds under the offering of approximately C\$10,574,763.

The offering was made through a syndicate of underwriters led by <u>Cormark Securities Inc</u>., and included Mackie Research Capital Inc.

Spectral, headquartered in Toronto, Ontario, is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of endotoxemic septic shock.

BLG represented Cormark Securities Inc. with a team led by <u>Philippe Tardif</u> that included <u>Linda Tu</u> and <u>Daniel</u> <u>Lang</u> (Tax).

For more information, please contact:

Tamara Costa National Director, Marketing and Communications Borden Ladner Gervais LLP <u>TCosta@blg.com</u> 416.350.2642

BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

blg.com

© 2025 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.